AstraZeneca warns UK on innovation

A decision by the UK’s National Health Service not to stock a new cancer drug being sold by AstraZeneca has seen the British pharmaceuticals company accuse the country of stymieing scientific innovation. The FT's Andrew Ward explains the predicament.